For Immediate Release
Chicago, IL – April 29, 2010 – Zacks.com announces the latest Industry Outlook. Today, Zacks Equity Research discusses the Pharma & Biotech Industry, including Mylan Inc (MYL), Pfizer (PFE), Eli Lilly (LLY), GlaxoSmithKline (GSK) and Sanofi-Aventis (SNY).
A synopsis of today’s Industry Outlook is presented below. The full article can be read at http://www.zacks.com/stock/news/33503/Pharma+%26amp%3B+Biotech+Stock+Review+-+April+2010.
One recent trend seen in the pharmaceutical sector is a focus on emerging markets. Companies like Mylan Inc (MYL), Pfizer (PFE), Eli Lilly (LLY), GlaxoSmithKline (GSK) and Sanofi-Aventis (SNY) are all looking to expand their presence in India, China, Brazil and other emerging markets. Until recently, most of the commercialization efforts were focused on the U.S. market — the largest pharmaceutical market — along with Europe and Japan.
However, emerging markets are slowly and steadily gaining more importance, and several companies are now shifting their focus to these areas. IMS Health estimates that these markets will grow 14-17% through 2014, while major developed markets will grow only 3-6%.
Although the U.S. will retain its position as the single largest market (estimated growth: 3-6% annually in the next five years), China will soon become the third largest market in the world. According to IMS Health, China’s pharmaceutical market is expected to continue to grow more than 20% annually, and contribute 21% of overall global growth through 2013. Growth in emerging markets could help stabilize the base business during the industry’s 2010-15 patent cliff.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5510.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it’s your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5511.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Contact:
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com
